26 May 2026
MAYER BROWN ADVISES SERB PHARMACEUTICALS ON THE AGREEMENT ENTERED INTO WITH HANSA BIOPHARMA AB TO ACQUIRE EUROPEAN AND MENA RIGHTS TO IDEFIRIX®(IMLIFIDASE)
Advising firms
Deal team
3 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Olivier Parawan Lead | Mayer Brown | Partner | Tax | Not stated |
| Jean-Philippe Coiffard | Mayer Brown | Counsel | Not stated | Not stated |
| Dominique Ehinger | Mayer Brown | Not stated | Not stated | Not stated |
Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- SERB Pharmaceuticals
- Counterparties
- Hansa Biopharma AB (Sell-side)